EHC Options Positioning Turns Sharply Defensive Before Monday's Print

Encompass Health has drifted to the bottom of its peer group on price momentum, down 3% over the past week against a median gain of roughly 0.5% for its closest healthcare services peers, including ENSG and ADUS.

The clearest divergence from peers, though, is in options positioning. Put buying has surged to levels that are strikingly unusual for this stock: the put/call ratio closed at 3.39 on Thursday, more than 2.5 standard deviations above its 20-day average of 0.77. That reading has held near that extreme for two consecutive sessions, suggesting this is deliberate positioning rather than a single day's noise. For context, the 52-week high on the ratio is 6.23, so there remains room for further defensive pressure, but the current level already marks a sharp break from the call-skewed profile that dominated the preceding weeks, when the PCR sat below 0.28.

The borrow market tells a calmer story. Availability is exceptionally loose at 5,420%, meaning far more shares are available to lend than are currently being borrowed. Borrowing costs are negligible at 0.34% annualised, and short interest itself is modest at 2.8% of the free float, down roughly 15% from a month ago. Whatever concern the options market is expressing, it has not translated into a push by short sellers to press new positions.

Analysts remain constructive heading into the Monday print. After EHC's Q2 beat, several firms raised targets: UBS moved to $155 from $150, Truist lifted to $150 from $140, and TD Cowen went to $140 from $125, all maintaining positive ratings. The consensus mean target of $148 sits about 19% above the current price of $124.09. The bull case centres on durable volume growth in a structurally undersupplied inpatient rehab market, low leverage, and management's willingness to fund de novo openings and bed additions from strong cash flow. Bears point to reimbursement risk: MedPAC's proposed -7% Medicare FFS IRF rate cut carries a potential roughly -18% adjusted EBITDA impact, and rising capex could approach 15% of revenues, compressing the free-cash yield that underpins much of the optimism.

Wikipedia page views for EHC are running well above their own 90-day history, with a retail attention z-score of 2.16, the highest reading of any dataset tracked for this name. That elevation in retail interest coincides with the pre-earnings window and is attention, not a revenue signal, but it does suggest the print is drawing a wider audience than usual.

Monday's report is therefore less a test of whether Encompass Health can grow and more a test of whether volume, margin, and guidance can hold up well enough against the reimbursement backdrop to justify a stock that has already recovered most of the ground analysts said it needed to cover.